April 24, 2019 / 7:25 AM / 6 months ago

BRIEF-Galapagos, MorphoSys Announce Initiation Of Gecko Phase 2 Study

April 24 (Reuters) - GALAPAGOS NV:

* ANNOUNCED ON TUESDAY INITIATION OF GECKO

* GECKO IS A PHASE 2 STUDY TESTING A SUBCUTANEOUS FORMULATION OF MOR106 IN COMBINATION WITH TOPICAL CORTICOSTEROIDS IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

* RECRUITMENT WILL TAKE PLACE IN THE U.S. AND CANADA

* STUDY IS INTENDED TO SERVE AS AN IND (INVESTIGATIONAL NEW DRUG) OPENER WITH THE U.S. FDA

Source text: bit.ly/2FqHED8

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below